- Home
- FBNC vs VRDN Comparison
FBNC vs VRDN Comparison
Compare FBNC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBNC
- VRDN
- Stock Information
- Founded
- FBNC 1934
- VRDN 2006
- Country
- FBNC United States
- VRDN United States
- Employees
- FBNC N/A
- VRDN N/A
- Industry
- FBNC Major Banks
- VRDN Medical Specialities
- Sector
- FBNC Finance
- VRDN Health Care
- Exchange
- FBNC Nasdaq
- VRDN Nasdaq
- Market Cap
- FBNC 1.7B
- VRDN 1.6B
- IPO Year
- FBNC N/A
- VRDN N/A
- Fundamental
- Price
- FBNC $41.71
- VRDN $16.27
- Analyst Decision
- FBNC Buy
- VRDN Buy
- Analyst Count
- FBNC 2
- VRDN 12
- Target Price
- FBNC $56.00
- VRDN $36.44
- AVG Volume (30 Days)
- FBNC 170.4K
- VRDN 979.5K
- Earning Date
- FBNC 01-29-2025
- VRDN 03-04-2025
- Dividend Yield
- FBNC 2.11%
- VRDN N/A
- EPS Growth
- FBNC N/A
- VRDN N/A
- EPS
- FBNC 1.84
- VRDN N/A
- Revenue
- FBNC $333,724,000.00
- VRDN $302,000.00
- Revenue This Year
- FBNC N/A
- VRDN $3.30
- Revenue Next Year
- FBNC $5.80
- VRDN N/A
- P/E Ratio
- FBNC $22.67
- VRDN N/A
- Revenue Growth
- FBNC N/A
- VRDN N/A
- 52 Week Low
- FBNC $29.53
- VRDN $11.40
- 52 Week High
- FBNC $50.34
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- FBNC 37.89
- VRDN 36.43
- Support Level
- FBNC $42.32
- VRDN $15.62
- Resistance Level
- FBNC $43.75
- VRDN $18.15
- Average True Range (ATR)
- FBNC 1.46
- VRDN 0.91
- MACD
- FBNC -0.22
- VRDN -0.20
- Stochastic Oscillator
- FBNC 3.90
- VRDN 14.48
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.